Our forward-looking approach drives breakthroughs
As an independent company, we don’t have to answer to Wall Street. That gives us freedom to work for you. To follow the science wherever it leads—so we can discover the breakthroughs that will change lives for you and your loved ones. To ensure you don’t have to worry about affordability and accessibility when you’re standing at the pharmacy counter. And to always think about our work in terms of human lives, not fiscal quarters.
You can see this come to life in our latest breakthrough treatment for chronic kidney disease. Originally developed to treat type 2 diabetes, our medication is available to help the more than 35 million people in the U.S. who have this condition. But 94% of patients with diabetes also have multiple other conditions, so we showed the world there’s still more to be done in this space. Today, we have one medication that treats type 2 diabetes, heart failure and chronic kidney disease—and now we can support over 800 million patients globally.
Taking this approach is often considered too costly or time consuming to other companies. But at Boehringer Ingelheim, we never abandon an area that could benefit lives if we have the potential for impact. Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.
Related Content
Chronic kidney disease
